These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2156 related items for PubMed ID: 21330184

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rationally designed nanovehicles to overcome cancer chemoresistance.
    Livney YD, Assaraf YG.
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1716-30. PubMed ID: 23954781
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
    Gillet JP, Gottesman MM.
    Drug Resist Updat; 2012 Nov; 15(1-2):2-4. PubMed ID: 22465109
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
    Xue X, Liang XJ.
    Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A, Folkman J.
    Drug Resist Updat; 2010 Feb; 13(1-2):16-28. PubMed ID: 20061178
    [Abstract] [Full Text] [Related]

  • 11. Molecular basis of antifolate resistance.
    Assaraf YG.
    Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The multi-factorial nature of clinical multidrug resistance in cancer.
    Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH.
    Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
    [Abstract] [Full Text] [Related]

  • 14. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.
    Colabufo NA, Contino M, Berardi F, Perrone R, Panaro MA, Cianciulli A, Mitolo V, Azzariti A, Quatrale A, Paradiso A.
    Toxicol In Vitro; 2011 Feb; 25(1):222-30. PubMed ID: 21078380
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review.
    Liu FS.
    Taiwan J Obstet Gynecol; 2009 Sep; 48(3):239-44. PubMed ID: 19797012
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
    Wang J, Tao X, Zhang Y, Wei D, Ren Y.
    Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 108.